Ascendis Pharma extends trial of growth hormone in adults
240 adults will continue receiving treatment with weekly growth hormone produced by Ascendis in a new study to determine the long-term efficacy and safety profile of the drug.
by mikkel aabenhus hemmingsen, translated by catherine brett
Ascendis Pharma will continue to test growth hormone lonapegsomatropin in adults to collect further data on the drug's efficacy and safety when used for a longer period.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin's dwarfism drug receives FDA approval
For subscribers
CHMP approves 13 new drugs
For subscribers
